Clinical Trial Update: Nitroprusside for Prevention of no-Reflow in Primary Angioplasty [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating nitroprusside to prevent no-reflow during primary angioplasty in myocardial infarction was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Nitroprusside (nitroprusside)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Myocardial Infarction | Phase 4 | Status: TERMINATED